CN Patent

CN107667092B — 作为fgfr4抑制剂的甲酰化n-杂环衍生物

Assigned to Novartis AG · Expires 2021-05-28 · 5y expired

What this patent protects

本发明提供式(I)化合物或其药学上可接受盐；制备所述化合物的方法，和其治疗应用。本发明还提供药理活性剂与含所述化合物的药物组合物的组合。

USPTO Abstract

本发明提供式(I)化合物或其药学上可接受盐；制备所述化合物的方法，和其治疗应用。本发明还提供药理活性剂与含所述化合物的药物组合物的组合。

Drugs covered by this patent

Patent Metadata

Patent number
CN107667092B
Jurisdiction
CN
Classification
—
Expires
2021-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.